Findings from Genentech Inc.'s randomized Phase III CLEOPATRA study of pertuzumab in HER2-positive metastatic breast cancer suggested the drug, in combination with Herceptin (trastuzumab) and docetaxel chemotherapy, provided a 38 percent improvement in progression-free survival (PFS) compared to Herceptin and docetaxel alone in previously untreated HER2-positive metastatic breast cancer (mBC).